|
Accession number;04A0309577
|
| Title;Study on G-CSF Regimen to Treat Leukopenia Induced by Cancer Chemotherapy |
| Author;
HAYASHI YUJI
(Sumitomo Metal Mining Co., Ltd., Sumitomo Besshi Hospital, JPN)
|
Journal Title;Japanese Pharmacology & Therapeutics
|
Journal Code:Z0947A
|
ISSN:0386-3603
|
|
VOL.32;NO.1;PAGE.41-44(2004)
|
| Figure&Table&Reference;FIG.1, TBL.2, REF.7 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;G-CSF has been demonstrated to be effective on leukopenia induced by cancer chemotherapy. The author administered nartograstim subcutaneously at a dose of 50 .MU.g in one course of cancer chemotherapy in 7 patients, 3 with ovarian tumor, 2 with uterine corpus cancer, and 2 with uterine cervical cancer, receiving two or more courses of the same chemotherapy. The necessity of administering G-CSF for consecutive days was studied by comparing the recovery of leukopenia between consecutive- and alternate-day regimens. The duration from the nadir to .GEQ.2000/mm3 or .GEQ.3000/mm3 of leukocyte count and the time-course profile at measuring points were superior by consecutive-day regimen than by alternate-day regimen. However, there was no statistically significant difference in any endpoint or in the time of dosing G-CSF. No infection occurred by consecutive- or alternate-day regimen. The administration of G-CSF on alternate days to treat myelosuppression induced by cancer chemotherapy seems to be a choice of regimen depending on leukocyte status of patients. (author abst.) |
|
|
|
Related Articles;
|
